GlassScriptPhysician profile
Micheal D Stephens
NPI 1659317980
$2,862.55
in general payments reported to CMS, 2019-2025
32 companies · $900 in 2025
The $900 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $66.76 · 2022: $13.20 · 2023: $689 · 2024: $666 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $448.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $332.49 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $251.84 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $237.68 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $191.57 | 2019-2025 | Vraylar, Linzess, Creon |
| Lilly USA, LLC | $162.85 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $150.50 | 2019-2025 | |
| Exact Sciences Corporation | $142.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $105.28 | 2023-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.01 | 2019-2025 | Jardiance |
| Abbott Laboratories | $61.04 | 2023-2025 | Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $56.41 | 2025 | Gemtesa |
| Corcept Therapeutics | $55.23 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $51.34 | 2019-2020 | |
| Axsome Therapeutics, INC. | $50.68 | 2023-2024 | Auvelity |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $48.86 | 2025 | |
| Neurocrine Biosciences, INC. | $47.22 | 2025 | |
| Allergan, INC. | $43.17 | 2019 | |
| Amarin Pharma, INC. | $41.58 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.56 | 2023-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $41.12 | 2019 | |
| Madrigal Pharmaceuticals | $35.83 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $24.61 | 2023 | Nuedexta |
| Sun Pharmaceutical Industries INC. | $24.41 | 2023 | Ilumya, Winlevi |
| Lundbeck LLC | $21.75 | 2025 | Rexulti |
| Ars Pharmaceuticals Operations, INC. | $20.55 | 2025 | Neffy |
| Eisai INC. | $18.90 | 2019 | |
| Dexcom, INC. | $17.59 | 2024 | Dexcom G6 Transmitter |
| Alkermes, INC. | $16.49 | 2019 | |
| Avanir Pharmaceuticals, INC. | $15.08 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.83 | 2019 | |
| Shire North American Group INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micheal Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.